Curis (CRIS) vs Lakewood-Amedex Biotherapeutics (LABT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Lakewood-Amedex Biotherapeutics is the larger company by market cap ($1.9 million vs $1.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRIS | LABT |
|---|---|---|
| Share price | $0.7094 | $0.792 |
| Market cap | $1.72M | $1.88M |
| 1-day change | -3.69% | -6.80% |
| P/E ratio (TTM) | 0.54 | — |
| EPS (TTM) | $1.32 | $-8.83 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $33.60 | $98.20 |
| 52-week low | $0.61 | $0.76 |
| Distance from 52-week high | -97.89% | -99.19% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +5914.94% | +1415.15% |
| Average volume | 199.15K | 2.50M |
| Shares outstanding | 2.43M | 2.37M |
| Employees | 20 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Curis
CRIS stock →Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 20 employees
About Lakewood-Amedex Biotherapeutics
LABT stock →Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
CRIS vs LABT FAQ
Which is bigger, Curis or Lakewood-Amedex Biotherapeutics?
Lakewood-Amedex Biotherapeutics (LABT) is larger, with a market capitalization of $1.88M compared with $1.72M for Curis (CRIS).
Are Curis and Lakewood-Amedex Biotherapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Curis and Biotechnology: Pharmaceutical Preparations for Lakewood-Amedex Biotherapeutics.